secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001104659-25-075268
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Q2 net loss $6.7M; cash runway into Q2 2026; clinical milestones
--------------------------------------------------------------------------------

- Net loss of $6.7M ($0.11 per share) vs. $7.0M ($0.18 per share) in Q2 2024.
- Cash and equivalents $11.6M; plus $41.9M in NIA grant funds; runway into Q2 2026.
- Surpassed 50% enrollment in Phase 2 START study of zervimesine in early Alzheimer's.
- EOP2 meeting with FDA held; breakthrough designation application for zervimesine in DLB pending.
- Positive Phase 2 dry AMD data showed 28.6% reduction in GA lesion growth at 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925075268/0001104659-25-075268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925075268/tm2522152d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-075268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer